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To the Editor
We read with great interest the article by Devaraj et al. 1 According to the authors, soluble Klotho protein (sKL) appears to be an effective biological factor related to diabetes and chronic kidney disease. However, there is a paucity of data on sKL levels in patients with cancer. Therefore, we put forward these questions: Can we detect the level of sKL in the serum samples of patients with cancer? Is there a difference in sKL levels between healthy people and patients with cancer? Can sKL be a potential tumor biomarker?
Some scholars have reported that Klotho may have a relation to tumorigenesis. [2] [3] [4] The Klotho gene has been found to function as an in vitro and in vivo tumor suppressor in breast, pancreatic, and other cancers by blocking the insulin-like growth factor 1/insulin and transforming growth factor β1 pathways. Tissue microarrays showed lower expression of Klotho protein in breast and pancreatic cancer tissues compared with normal tissues. It was estimated that the expression of Klotho was restrained in the process of tumorigenesis. Two forms of Klotho exist, membrane and secreted, the latter produced by the shedding of the transmembrane protein. To date, it has not been reported whether sKL is related to human tumor. So the first step
